April 2026 Research Update

This month included a Europe-wide look at how LAM care is organized, with a clear message that care and research are harder when data and experience are spread across many centers. The paper argues that a shared European registry and trial network could make it easier to collect the same core information in the same way across countries. The practical point is not about a new medicine, but about building the infrastructure that can speed up learning and make future studies more coordinated. [1]

The proposed European LAM Registry is described as a way to standardize data collection and support clinical research across borders. It is also presented as a foundation for a coordinated trial network, which could make it easier to run studies in a rare disease where any single center may see relatively few patients. The article frames these steps as a platform for collaboration rather than reporting patient outcomes yet. [1]

For patients and caregivers, this work mainly matters for the future rather than changing anything right now. The idea is that a shared registry and trial network could make research faster and more comparable between countries, which may help answer practical questions about LAM over time. What remains uncertain is how quickly such a registry will be created, what data will be included, and how directly it will improve access or outcomes, because this paper is a call to organize care and research rather than a results report. [1]

This month added a clearer picture of how hormone signaling and inflammation-like signaling may reinforce each other in LAM, based on lab work using patient samples and LAM-like cells. The study reported higher IL-6 (an immune signaling protein) in LAM lung tissue and higher IL-6 in blood compared with controls, and it also reported that higher IL-6 in blood went along with worse lung function. In cell experiments, estrogen and IL-6 increased signals linked to cell growth and movement, and blocking the estrogen receptor and STAT3 pathways together significantly reduced proliferation and migration in the TSC2-deficient cells. [2]

In experiments using TSC2-deficient cells (a commonly used LAM model), estrogen and added IL-6 increased IL-6 and estrogen receptor signals over time. Blocking STAT3 reduced estrogen receptor signals, while blocking the estrogen receptor alone did not clearly reduce IL-6 in these experiments. When both pathways were blocked together using fulvestrant and Stattic, the cells showed a significant reduction in proliferation and migration, which are lab measures of aggressive cell behavior. [2]

For patients, this is early research that helps explain why LAM can be influenced by hormones and may also involve immune signaling, but it does not show that a new treatment works in people. The reported link between higher blood IL-6 and worse lung function suggests IL-6 could be explored as a marker of disease activity, although the study does not establish how it should be used in routine care. What remains uncertain is whether targeting these pathways will be safe or effective in patients, since the treatment-like findings here come from laboratory and patient-sample work rather than clinical trials. [2]

This month included individual patient reports showing that LAM can be missed or confused with other lung conditions, especially when a person has overlapping symptoms or another lung disease at the same time. Across the cases, the final diagnosis depended on examining lung tissue closely, sometimes only after surgery or transplant. The shared message is that unusual presentations and co-existing diseases can complicate the path to a clear diagnosis. [3] [4]

In one report, a woman previously labeled as having idiopathic pulmonary hemosiderosis was found to have LAM only after her lungs were removed during urgent bilateral lung transplantation, highlighting how difficult diffuse lung diseases can be to tell apart. The report also noted the use of VA-ECMO support during the transplant surgery, but the abstract did not provide longer-term outcomes. This case emphasizes that the most definitive answers sometimes come from tissue examination, even late in the disease course. [3]

In another report, a woman had pulmonary LAM described as complicated by pulmonary tuberculosis, and the diagnosis was built from imaging plus detailed tissue testing, including immunohistochemistry and a reported BRAF V600E mutation. The case involved surgical wedge removal of a lung area and pleurodesis, reflecting how procedures may be needed when there are nodules, collapsed lung, or fluid around the lung along with cystic lung disease. Because this is a single case with a literature review, it mainly illustrates what can happen rather than how often it happens. [4]

For patients and caregivers, these reports mainly add understanding about diagnosis rather than pointing to a new treatment. They show that LAM can look like other conditions, and that co-existing problems like infections may further blur the picture, so the final diagnosis may depend on specialized tissue testing. What remains uncertain is how common these specific situations are, because case reports describe one person at a time and cannot predict an individual patient's course. [3] [4]